GLP-1 programs the neurovascular landscape
Cell Metabolism · 2024
DOI: 10.1016/j.cmet.2024.09.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell Metabolism, 2024. Verfasst von Bandy Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Neurovascular Control of Homeostasis, Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, C…. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 199 Literaturangaben. Gefördert von: New York Academy of Medicine, National Institute of Diabetes and Digestive and Kidney Diseases Division of Diabetes Endocrinology and Metabolic Diseases, E Matilda Ziegler Foundation for the Blind Inc.
Abstract (Originalsprache)
Readily available nutrient-rich foods exploit our inherent drive to overconsume, creating an environment of overnutrition. This transformative setting has led to persistent health issues, such as obesity and metabolic syndrome. The development of glucagon-like peptide-1 receptor (GLP-1R) agonists reveals our ability to pharmacologically manage weight and address metabolic conditions. Obesity is directly linked to chronic low-grade inflammation, connecting our metabolic environment to neurodegenerative diseases. GLP-1R agonism in curbing obesity, achieved by impacting appetite and addressing associated metabolic defects, is revealing additional benefits extending beyond weight loss. Whether GLP-1R agonism directly impacts brain health or does so indirectly through improved metabolic health remains to be elucidated. In exploring the intricate connection between obesity and neurological conditions, recent literature suggests that GLP-1R agonism may have the capacity to shape the neurovascular landscape. Thus, GLP-1R agonism emerges as a promising strategy for addressing the complex interplay between metabolic health and cognitive well-being.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Neurovascular Control of Homeostasis, Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT, USA. Electronic address: bac008@health.ucsd.edu.
- State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China.
- Departments of Medicine (Endocrinology & Metabolism) and Pediatrics (Pediatric Endocrinology), Yale University School of Medicine, New Haven, CT, USA.
- Department of Genetics, Yale University School of Medicine, New Haven, CT, USA.
- Helmholtz Zentrum München, Neuherberg, Germany; Division of Metabolic Diseases, Department of Medicine, Technische Universität München, München, Germany.
- Laboratory of Neurovascular Control of Homeostasis, Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT, USA; Wu Tsai Institute for Mind and Brain, Yale University, New Hav…
Förderung
- New York Academy of Medicine
- National Institute of Diabetes and Digestive and Kidney Diseases Division of Diabetes Endocrinology and Metabolic Diseases
- E Matilda Ziegler Foundation for the Blind Inc
Zitieren
APA
Chen, B., Yu, X., Horvath-Diano, C., Ortuño, M. J., Tschöp, M. H., Jastreboff, A. M., & Schneeberger, M. (2024). GLP-1 programs the neurovascular landscape. Cell Metabolism. https://doi.org/10.1016/j.cmet.2024.09.003
Vancouver
Chen B, Yu X, Horvath-Diano C, Ortuño MJ, Tschöp MH, Jastreboff AM, et al. GLP-1 programs the neurovascular landscape. Cell Metabolism. 2024. doi:10.1016/j.cmet.2024.09.003
BibTeX
@article{Chen2024,
author = {Chen, Bandy and Yu, Xiaofei and Horvath-Diano, Claudia and Ortuño, María José and Tschöp, Matthias H and Jastreboff, Ania M and Schneeberger, Marc},
title = {GLP-1 programs the neurovascular landscape},
journal = {Cell Metabolism},
year = {2024},
doi = {10.1016/j.cmet.2024.09.003}
}
EUVIMED